Considering the lower accuracy of predicting the response in colorectal cancers than in melanomas (as described in the TIDE introduction), we utilized a subclass mapping algorithm to compare the RNA profiles of the IPM-risk groups with another published dataset containing 47 cases of melanoma that responded to anti-PD-1 and anti-CTLA-4 immunotherapies (Roh et al., 2017). The gene discussed is CTLA4; the disease is melanoma.